RSLV-132 / Platform

About Resolve Therapeutics

Resolve Therapeutics is pioneering a novel therapeutic approach that targets extracellular RNA and DNA as a fundamental driver of inflammation. Its lead asset, RSLV-132, is an Fc-fusion nuclease in Phase 2 trials for Sjögren's disease, with prior clinical data generated in lupus and Long COVID. The company is leveraging its platform to address both chronic autoimmune conditions and acute inflammatory settings like polytrauma, positioning itself in a high-unmet-need market with a potentially differentiated, non-immunosuppressive mechanism.

About Resolve Therapeutics

Resolve Therapeutics is pioneering a novel therapeutic approach that targets extracellular RNA and DNA as a fundamental driver of inflammation. Its lead asset, RSLV-132, is an Fc-fusion nuclease in Phase 2 trials for Sjögren's disease, with prior clinical data generated in lupus and Long COVID. The company is leveraging its platform to address both chronic autoimmune conditions and acute inflammatory settings like polytrauma, positioning itself in a high-unmet-need market with a potentially differentiated, non-immunosuppressive mechanism.

Therapeutic Areas